Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | UBE2N | P61088 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754078 | 1.00 | GPR84 (0.46) | GPR84SPHK1FFAR1LMNACYP2D6 | |
| SCHEMBL758208 | 1.00 | GPR84 (0.46) | GPR84SPHK1FFAR1LMNACYP2D6 | |
| SCHEMBL756183 | 1.00 | GPR84 (0.46) | GPR84SPHK1FFAR1LMNACYP2D6 | |
| SCHEMBL28854810 | 1.00 | GPR84 (0.46) | GPR84SPHK1FFAR1LMNACYP2D6 | |
| SCHEMBL3925045 | 1.00 | GPR84 (0.46) | GPR84SPHK1FFAR1LMNACYP2D6 | |
| SCHEMBL755333 | 1.00 | GPR84 (0.46) | GPR84SPHK1FFAR1LMNACYP2D6 | |
| SCHEMBL756127 | 1.00 | GPR84 (0.46) | GPR84SPHK1FFAR1LMNACYP2D6 | |
| SCHEMBL753596 | 1.00 | GPR84 (0.46) | GPR84SPHK1FFAR1LMNACYP2D6 | |
| SCHEMBL756050 | 1.00 | GPR84 (0.46) | GPR84SPHK1FFAR1LMNACYP2D6 | |
| Bromide SCHEMBL29184042 | 0.98 | GPR84 (0.45) | GPR84SPHK1FFAR1LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10423084-B2 | Method for producing liquid developer | CANON KABUSHIKI KAISHA (JP) | 2019-09-24 | — | — | US | disclosed |
| US-20190271929-A1 | LIQUID DEVELOPER AND METHOD FOR MANUFACTURING LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2019-09-05 | — | — | US | disclosed |
| US-20190155180-A1 | METHOD FOR PRODUCING LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2019-05-23 | — | — | US | disclosed |
| US-10175597-B2 | Liquid developer and method of producing same | CANON KABUSHIKI KAISHA (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20180348658-A1 | CURABLE LIQUID DEVELOPER AND METHOD FOR PRODUCING CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2018-12-06 | — | — | US | disclosed |
| EP-3410217-A1 | CURABLE LIQUID DEVELOPER AND METHOD FOR PRODUCING CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2018-12-05 | — | — | EP | disclosed |
| US-20180329333-A1 | CURABLE LIQUID DEVELOPER AND METHOD FOR MANUFACTURING CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2018-11-15 | — | — | US | disclosed |
| EP-3401735-A1 | CURABLE LIQUID DEVELOPER AND METHOD FOR MANUFACTURING CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2018-11-14 | — | — | EP | disclosed |
| US-20180210362-A1 | METHOD OF PRODUCING CURABLE LIQUID DEVELOPER AND CURABLE LIQUID DEVELOPER | CANON KK (JP) | 2018-07-26 | — | — | US | disclosed |
| EP-3098657-B1 | ULTRAVIOLET-CURABLE LIQUID DEVELOPER AND METHOD OF PRODUCING SAME | CANON KK (JP) | 2018-07-18 | — | — | EP | disclosed |
| US-20150192875-A1 | ULTRAVIOLET-CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2015-07-09 | — | — | US | disclosed |
| EP-2230283-B1 | Actinic energy radiation curable ink-jet ink and ink-jet recording method | KONICA MINOLTA IJ TECHNOLOGIES (JP) | 2014-07-02 | — | — | EP | disclosed |
| US-8507583-B2 | Actinic energy radiation curable ink-jet ink and ink-jet recording method | KONICA MINOLTA IJ TECHNOLOGIES, INC. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20130044168-A1 | INK-JET IMAGE FORMING METHOD AND INK-JET INK SET | KONICA MINOLTA HOLDINGS, INC. (JP) | 2013-02-21 | — | — | US | disclosed |
| EP-2228415-B1 | Actinic energy radiation curable ink-jet ink, ink-jet recoring method, and printed matter | KONICA MINOLTA IJ TECHNOLOGIES (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20100255211-A1 | ACTINIC ENERGY RADIATION CURABLE INK-JET INK AND INK-JET IMAGE FORMING METHOD | KONICA MINOLTA IJ TECHNOLOGIES, INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2236568-A1 | Actinic energy radiation curable ink-jet ink and ink-jet image forming method | Konica Minolta IJ Technologies, Inc. (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-20100239777-A1 | ACTINIC ENERGY RADIATION CURABLE INK-JET INK AND INK-JET RECORDING METHOD | KONICA MINOLTA IJ TECHNOLOGIES, INC. (JP) | 2010-09-23 | — | — | US | disclosed |
| EP-2230283-A1 | Actinic energy radiation curable ink-jet ink and ink-jet recording method | Konica Minolta IJ Technologies, Inc. (JP) | 2010-09-22 | — | — | EP | disclosed |
| EP-2228415-A1 | Acting energy radiation curable ink-jet ink, ink-jet recoring method, and printed matter | Konica Minolta IJ Technologies, Inc. (JP) | 2010-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10175597-B2 | Liquid developer and method of producing same | AUP1, RCC1, CBR1 | GPR84 2258/4885SPHK1 1048/4885FFAR1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.